The partial hold was lifted. The shorting is down. Some large brokerages, even Goldman Sachs, have been handcuffed from using their F3 keys to otherwise (wittingly or unwittingly) facilitate unwarranted naked shorting. The move to OTC reduced shorting. MFN has been (and I think still is) removed. The trial is nearing an end for better or worse. I think better. We see from shipment documents that a great deal of money must be being spent on manufacturing preparation. You can worry about the SEC inquiry, but I'm guessing many matters have been resolved since the original investigation began. Could something play havoc on the trial? I don't think so because the partial clinical hold was lifted, telling me there is an adequate and well controlled trial. Again, I think many matters were cleaned up and/or resolved along the way. That's just my sense.
News 
Market Data 
Discover 
